Betamethasone and dexamethasone are the most widely studied antenatal corticosteroids (ACS) administered to pregnant women, just prior to the birth of a preterm neonate, to accelerate fetal lung maturation. Although betamethasone, predominantly used in developed countries, has been shown to be an effective and safe intervention for reducing neonatal mortality, the choice of ACS and optimal dosing in low and middle income countries (LMICs) remains unclear. This is primarily because the exposure-response relationships have not been established for ACS despite the long history of use. As the first step toward the optimal use of ACS in LMICs, we developed physiologically-based pharmacokinetic (PBPK) models to describe the kinetics of ACS following i.v., p.o., or i.m. dosing. In vitro data describing the cytochrome P450 3A4 enzyme contribution were incorporated and this was refined using clinical data. The models can be applied prospectively to predict kinetics of ACS in pregnant women receiving various dosing regimens.Preterm birth is a major cause of death and morbidity in newborns worldwide and the majority of preterm deliveries and deaths occur in sub-Saharan African and South Asian countries. 1 Respiratory morbidity, including respiratory distress syndrome (RDS), is a serious complication of preterm birth and the primary cause of early neonatal mortality and disability. The administration of antenatal corticosteroids (ACS) to a pregnant woman (who is at risk of imminent preterm birth) is recommended to promote fetal